Share this article
Share this article
Galderma is partnering with popular Canadian influencers to launch #RosaceaChallenge, challenging sufferers to face up to rosacea and carry on doing the activities they love
Thanks to advances in dermatology practice, the campaign urges rosacea sufferers to visit a family physician or dermatologist to discuss a personalized treatment plan to help them aim for clear skin
TORONTO, April 8, 2021 /CNW/ - This Rosacea Awareness Month, Galderma, the world s largest dermatology company, is collaborating with Canadian actress, Christine Solomon, and a team of influencers to launch a skin positivity movement. The #RosaceaChallenge encourages Canadians frustrated with this chronic skin condition to take action by consulting with a dermatologist or their family physician, as a first step in achieving clearer skin.
Fifth indication for DUPIXENT
® in Canada following approvals for moderate-to-severe atopic dermatitis in adults and adolescents, severe chronic rhinosinusitis with nasal polyposis, and severe asthma in adults and adolescents.
For those living with atopic dermatitis, itch has the highest impact on a patient s quality of life.
1
Results from a survey conducted among Canadian children with atopic dermatitis found that 70 per cent experienced loss of sleep and 30 per cent experienced anxiety due to their condition.
2
MISSISSAUGA, ON, Feb. 23, 2021 /CNW/ - Sanofi Canada announced today that Health Canada has approved DUPIXENT
® (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis (AD) in children aged six to 11 years whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.